Loading...
•
Jun 30, 2025
Cibus Q2 2025 Earnings Report
Cibus reported its second quarter financial results for 2025, highlighting continued progress in its Rice herbicide tolerance traits and partner-funded sustainable ingredients programs, alongside efforts to streamline operations and reduce cash usage.
Key Takeaways
Cibus, Inc. reported a net loss of $26.6 million for Q2 2025, an improvement from $28.5 million in the prior year. The company generated $933,000 in revenue and ended the quarter with $36.5 million in cash and cash equivalents. Operational focus remains on advancing Rice herbicide tolerance traits and partner-funded sustainable ingredients programs, with an aim to reduce annual cash usage to approximately $30 million by 2026.
Net loss improved to $26.6 million in Q2 2025 from $28.5 million in Q2 2024, reflecting the impact of cost reduction initiatives.
Revenue for the quarter was $933,000, showing an increase compared to the prior year's $838,000.
Cash and cash equivalents stood at $36.5 million as of June 30, 2025, supported by a recent $27.5 million public offering.
The company is on track for initial commercial launches of Rice herbicide tolerance traits in Latin America by 2027 and expects nominal revenues from sustainable ingredients biofragrance products in 2025.
Forward Guidance
Cibus anticipates reducing its annual cash usage to approximately $30 million by 2026 through operational streamlining. The company expects initial royalty revenue from Rice herbicide tolerance traits starting in Latin America in 2027 and nominal revenues from sustainable ingredients biofragrance products in 2025, with commercial expansion planned for 2026.
Positive Outlook
- Targeting initial commercial launch of Rice herbicide tolerance traits (HT1 and HT3) in Latin America by 2027 and U.S. in 2028, with potential annual accessible royalties over $200 million.
- Expected reduction of annual cash usage to approximately $30 million by 2026 due to streamlining operational focus.
- On track for planned nominal revenues in 2025 from partner-funded and/or supported sustainable ingredients products, with targeted commercial expansion in 2026.
- Global regulatory environment remains supportive of gene editing technologies, with positive developments in EU, Ecuador, India, Asia, and U.S. markets.
- Raised $27.5 million in gross proceeds from a public offering, extending cash runway into Q2 2026.
Challenges Ahead
- The EU regulatory process for New Genomic Techniques (NGTs) did not reach final agreement by June 30, 2025, as initially anticipated.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...